· For research use only. Not for human consumption.
For research use only. Not for human consumption.
If you’ve heard about GLP-3 and want to know what the actual science says — not the hype, not the speculation — this is where to start. GLP-3 studies published in peer-reviewed journals are the only reliable source of information about how this compound behaves. Everything else is guesswork.
As of early 2026, two major GLP-3 studies have been published in The Lancet, one of the world’s most respected scientific journals. Both were carefully controlled, independently reviewed, and designed to meet the highest standards of biomedical research. This post walks you through both studies in plain English — what they tested, how they were designed, and what the findings mean.
No chemistry degree required. If you want the basics first, start with our beginner’s guide to GLP-3.
TL;DR: Two landmark GLP-3 studies have been published: Urva et al. (2022) in a phase 1b multiple-ascending dose trial (PMID: 36354040), and Rosenstock et al. (2023) in a larger phase 2 randomized controlled trial (PMID: 37385280). Both appeared in The Lancet and examined this triple incretin receptor agonist analog under rigorous research conditions. For research use only. Not for human consumption.
Why Published GLP-3 Studies Matter
Before diving into the specific studies, it’s worth explaining why published research matters so much. In science, a claim isn’t considered credible until it’s been:
- Written up formally — with methods, data, and analysis fully documented
- Peer-reviewed — evaluated by independent experts who didn’t participate in the study
- Published in a reputable journal — meaning the editorial board agreed the work meets their standards
Both GLP-3 studies cleared all three hurdles and were published in The Lancet. That’s significant because The Lancet accepts only a small fraction of submitted studies. Getting published there means the research was considered important, well-designed, and scientifically sound by multiple independent reviewers.
Study 1: Urva et al. (2022) — The First Published GLP-3 Data
This was the first major published study on GLP-3’s triple agonist compound. Here’s what you need to know about it:
What Kind of Study Was It?
It was a phase 1b, multiple-ascending dose trial. Let’s translate that:
- Phase 1b means it was one of the earliest stages of formal research, focused on understanding basic behavior and characterizing the compound’s profile
- Multiple-ascending dose means researchers tested several different amounts, starting low and gradually increasing, to see how the compound’s activity changed at each level
How Was It Designed?
The study was:
- Multicentre — conducted at multiple research sites (not just one lab)
- Double-blind — neither the researchers nor the participants knew who received the active compound versus placebo
- Placebo-controlled — some participants received an inactive substance for comparison
- Randomised — participants were randomly assigned to groups, reducing bias
This design is considered the gold standard for generating reliable scientific data. It minimizes the chance that the results are influenced by expectations or coincidence.
Urva S, Coskun T, Loh MT, et al. (2022). “LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.” Lancet, 400(10366), 1869-1881. (PMID: 36354040)
Study 2: Rosenstock et al. (2023) — The Phase 2 Expansion
Building on the Urva study, the Rosenstock study was larger and more comprehensive:
What Made This Study Bigger?
- Phase 2 — a step beyond phase 1b, designed to examine the compound’s activity across a wider range of parameters
- Active comparator — in addition to placebo, the study included an active comparison group, which gives researchers a reference point beyond just “something vs nothing”
- Parallel-group design — participants stayed in their assigned group for the duration of the study, allowing cleaner comparisons
Why This Study Matters
Phase 2 GLP-3 studies represent a critical step in the research pipeline. Phase 1 establishes that a compound can be characterized safely. Phase 2 starts asking the bigger questions: How does the compound behave across different conditions? What happens at different research parameters? How does it compare to existing approaches?
Rosenstock J, Frias JP, Jastreboff AM, et al. (2023). “A GIP, GLP-1 and glucagon receptor agonist for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial.” Lancet, 402(10401), 529-544. (PMID: 37385280)
What These GLP-3 Studies Tell Us (And What They Don’t)
What they tell us:
- A triple agonist compound engaging GLP-1, GIP, and glucagon receptors can be characterized in controlled research settings
- The compound’s activity profile differs from single and dual agonist approaches
- The research design was rigorous enough to publish in one of the world’s top journals — twice
What they don’t tell us:
- Long-term behavior — both studies were relatively short in duration
- Broader population data — the studies had specific inclusion criteria
- Comparative advantage — more head-to-head research with other compound classes is needed
This is why GLP-3 remains a research compound. The published data is promising but preliminary. Much more work needs to be done before the scientific community fully understands this class of molecules.
Where to Read the Original GLP-3 Studies
Both studies are freely accessible via PubMed:
PubMed is the U.S. National Library of Medicine’s database of biomedical literature. It’s free to search, and most study abstracts (summaries) are available without a subscription.
For research-grade GLP-3 with batch-specific COAs and third-party verification, visit the Alpha Peptides GLP-3 product page or browse our full Certificate of Analysis library.
Frequently Asked Questions About GLP-3 Studies
How many GLP-3 studies have been published?
As of early 2026, two major GLP-3 studies have been published in The Lancet. Additional research is underway but has not yet been published in peer-reviewed form.
What journal published the GLP-3 studies?
The Lancet, one of the oldest and most respected medical journals in the world, founded in 1823. Publication in The Lancet is considered a strong indicator of scientific significance.
Are GLP-3 studies available to the public?
Yes. You can access the study abstracts for free on PubMed. Full-text access may require a journal subscription, but the abstracts provide detailed summaries of the methods, results, and conclusions.
What’s the difference between phase 1 and phase 2 GLP-3 studies?
Phase 1 studies focus on basic characterization — understanding how the compound behaves at different levels. Phase 2 studies are larger and start examining the compound’s activity across broader research parameters with more rigorous comparison groups.
Will there be more GLP-3 studies?
Yes. Research on triple incretin receptor agonist analogs is an active and growing field. Additional studies are expected to be published as the research pipeline advances.
For research use only. Not for human consumption. This article is for informational purposes and does not constitute medical advice, dosing guidance, or therapeutic recommendations.
